Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28132681 | 0.90 | KDM1A (0.35) | DPP4DPP8KDM1A | |
| Trifluoroacetic Acid SCHEMBL14738636 | 0.89 | DPP4 (0.33) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3899456 | 0.89 | DPP4 (0.33) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL31630320 | 0.89 | DPP4 (0.33) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28133460 | 0.83 | OAT (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3154232 | 0.83 | OAT (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL23671375 | 0.82 | DPP4 (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL16818510 | 0.82 | DPP4 (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL16818579 | 0.82 | DPP4 (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3025153 | 0.81 | OAT (0.36) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | DPP4 4642/4885DPP8 4561/4885KDM1A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.